Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Gene therapy against hemophilia

Hannover Medical School (MHH) is one of the first institutions in Germany to be authorized to carry out a new innovative treatment for haemophilia A and B

07-Oct-2024 - Cell and gene therapies are on the rise. This is a new glimmer of hope for people with previously untreatable or barely treatable diseases. Another new therapeutic method has now been added to the list: gene therapy for hemophilia, also known as bleeding disorder. The Hemophilia Center at ...

AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage

04-Sep-2023 - AaviGen GmbH, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, announced the completion of its 17M € Series B financing round. Building on AaviGen’s proprietary portfolio of engineered cardiac-specific ...

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement

11-Jan-2022 - Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ ...

Sartorius acquires majority stake in CellGenix

Portfolio expanded by cell culture components, such as growth factors, cytokines, and media

05-Jul-2021 - The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the biotechnology hub in Boston, Massachusetts USA, produces and ...

Successful Exit: PerkinElmer Agrees to Acquire SIRION Biotech

SIRION Biotech will continue to grow its position in viral vector technologies for cell and gene therapy as part of PerkinElmer

24-Jun-2021 - High-Tech Gründerfonds, Creathor Ventures, KfW and Bayern Kapital announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. This news comes after ...

Spin-off offers purification tool to tackle viral gene therapy manufacturing bottlenecks

Higher speed and increased yield thanks to membrane-based steric exclusion chromatography

22-Jun-2021 - ContiVir, a spin-off project at the Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg, has published results in the scientific journal Human Gene Therapy detailing the purification of Adeno-associated virus (AAV) using membrane-based steric exclusion chromatography (SXC), a ...

Advance Gene Therapy Pipeline for Musculoskeletal Diseases

GeneQuine Biotherapeutics Secures more than €9 Million

28-Jan-2021 - GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has raised €5.4 million in Series A financing and €3.65 million non-dilutive funding bringing the total amount raised to €9.05 million. The Series A ...

ViGeneron and Biogen collaborate

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

05-Jan-2021 - ViGeneron GmbH announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV ...

Restoring vision by gene therapy

Latest scientific findings give hope for people with incurable retinal degeneration

09-Jun-2020 - Humans rely dominantly on their eyesight. Losing vision means not being able to read, recognize faces or find objects. Macular degeneration is one of the major reasons for visual impairment, round the globe, close to 200 million people are affected. Photoreceptors in the retina are responsible to ...